Allspring Global Investments Holdings LLC Increases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Allspring Global Investments Holdings LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 16,717.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 85,434 shares of the biotechnology company's stock after buying an additional 84,926 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.09% of Sarepta Therapeutics worth $10,602,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wellington Management Group LLP raised its position in shares of Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Erste Asset Management GmbH bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $79,425,000. Janus Henderson Group PLC raised its position in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Soros Fund Management LLC bought a new position in shares of Sarepta Therapeutics in the 3rd quarter worth approximately $25,800,000. Finally, Swedbank AB bought a new position in shares of Sarepta Therapeutics in the 4th quarter worth approximately $16,706,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Piper Sandler decreased their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research report on Wednesday, November 27th. Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Guggenheim increased their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "sell" rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Finally, Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $176.77.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $2.13 on Friday, reaching $106.28. The stock had a trading volume of 709,164 shares, compared to its average volume of 811,167. The stock has a market cap of $10.15 billion, a P/E ratio of 85.02 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 1 year low of $101.15 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The company has a 50 day simple moving average of $117.88 and a 200 day simple moving average of $123.85.

Insider Transactions at Sarepta Therapeutics

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.